Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolysis in thromboembolic diseases

D C Gulba1, R Dechend

  • 1UKRV-Franz-Volhard Hospital, Berlin, Germany.

Annals of Hematology
|October 1, 1994
PubMed
Summary

Thrombolysis offers an alternative to surgery for thromboembolic disease but carries bleeding risks. Newer agents and careful management improve safety and efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

State of the art approach to managing angina and ischemia: tailoring treatment to the evidence.

European journal of internal medicine·2021
Same author

The ESC 2019 CCS guidelines: Have we left our patients and scientific evidence behind?

European journal of internal medicine·2019
Same author

Lymphocyte characterization of decidua basalis spiral arteries with acute atherosis in preeclamptic and normotensive pregnancies.

Journal of reproductive immunology·2019
Same author

[Anticoagulation in patients with chronic kidney disease : Recommendations from the working group "Heart-Kidney" of the German Cardiac Society and the German Society of Nephrology].

Der Internist·2017
Same author

[Non-vitamin K dependent oral anticoagulants : What is important in intensive care medicine].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2017
Same author

The association between angiogenic markers and fetal sex: Implications for preeclampsia research.

Journal of reproductive immunology·2016

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Pharmacology

Background:

  • Thrombolysis is a key treatment for thromboembolic diseases, presenting an alternative to surgical interventions.
  • The decision to use thrombolysis requires balancing potential benefits against the inherent risk of bleeding.

Purpose of the Study:

  • To review the considerations for selecting thrombolytic agents and regimens.
  • To discuss the management of bleeding complications and the safety profile of newer agents.

Main Methods:

  • Review of therapeutic strategies for thrombolysis.
  • Analysis of risks and benefits associated with different thrombolytic regimens.
  • Evaluation of adjunctive therapies like heparin and reversal agents.

Main Results:

  • Thrombolytic efficacy and bleeding risk are influenced by agent choice, dosage, and duration.
  • High-dose, short-duration regimens may offer faster reperfusion but can be incomplete.
  • Longer-duration, lower-dose regimens risk delayed reperfusion, while bleeding risk increases with thrombolysis duration.

Conclusions:

  • Thrombolysis requires careful risk-benefit assessment and consideration of reperfusion urgency.
  • Adjunctive heparin is crucial, and newer fibrin-specific agents offer improved safety due to short half-lives and readily available antagonists for bleeding reversal.

Related Experiment Videos